Related Experiment Video
Updated: May 8, 2026
09:36
Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
Published on: February 5, 2019
Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles
Hamed Laroui1, Duke Geem2, Bo Xiao1
1Department of Chemistry and Biology, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|September 13, 2013
Summary
Nanoparticles loaded with CD98 siRNA effectively reduced intestinal inflammation in a mouse model. This targeted delivery system offers a promising therapeutic strategy for inflammatory bowel disease by downregulating CD98 expression.
Area of Science:
- Gastroenterology
- Nanomedicine
- Immunology
Background:
- Intestinal CD98 expression is vital for gut homeostasis and immune responses.
- Modulating CD98 offers a therapeutic avenue for inflammatory intestinal diseases like inflammatory bowel disease.
Purpose of the Study:
- To develop and evaluate nanoparticles (NPs) for targeted delivery of CD98 siRNA to intestinal cells.
- To assess the therapeutic efficacy of these NPs in reducing CD98 expression and mitigating colitis.
Main Methods:
- Characterization of CD98 siRNA/polyethyleneimine (PEI)-loaded NPs using physical chemistry techniques.
- Assessment of NP toxicity and biocompatibility with intestinal cells.
- Oral administration of NPs in a hydrogel to a dextran sodium sulfate-induced colitis mouse model.
Main Results:
- CD98 siRNA/PEI-loaded NPs were characterized with a diameter of ~480 nm and zeta potential of -5.26 mV.
- NPs demonstrated biocompatibility and protected siRNA from degradation.
- Oral administration reduced CD98 expression in mouse colonic tissues and ameliorated colitis.
- Flow cytometry confirmed CD98 downregulation in intestinal epithelial cells and macrophages.
Conclusions:
- Hierarchical nano-micro particles demonstrate colon-homing capabilities for targeted CD98 siRNA delivery.
- This approach effectively reduces CD98 expression in colonic cells, offering a therapeutic strategy for colitis.
- The study highlights the potential of NPs as a treatment for inflammatory intestinal diseases.
